-

Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first approach to weight loss is driving meaningful, sustainable results, laying the groundwork for lasting success. In a first-of-its-kind U.S. analysis of treatment plans, including compounded GLP-1s, customers taking a compounded GLP-1 reported losing an average of 20.9 pounds or 10.3% of initial body weight, within six months, while reporting a low rate of side effects. Just as importantly, 75% of customers remained on treatment plans in the same timeframe, a powerful signal of real-world trust and clinical success.1

Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a holistic weight loss program that combines personalized dosing when clinically necessary, 24/7 care team access, and educational support across nutrition, mental health, and physical wellness. The result: a scalable, high-quality model that empowers individuals, builds long-term trust, and helps people succeed.

Key findings from the new analysis indicate:

  • Holistic model helps people stick with their treatment: While dropout rates for commercially available GLP-1s can hover around 80% at six months2, only 25% of Hims & Hers customers discontinued treatment in that timeframe, highlighting the strength and confidence a holistic, personalized model delivers. While these results cannot be directly compared, it is encouraging that Hims & Hers customers appear to stick to their treatment plans in high numbers.
  • Personalized treatment plans drive significant weight loss, with low rates of side effects and high safety: Customers lost an average of 20.9 pounds, or 10.3% of their initial body weight in six months. Among these same customers, only 10.3% reported side effects, and an even smaller 4.5% reported intolerable side effects. Among those who completed a 6-month check-in, 97% of customers on plans with compounded GLP-1s reported an improvement in their overall health.
  • Always-on support empowers customers beyond the prescription: The platform combines 24/7 care team access with curated education across nutrition, mental health, and physical wellness. Customers exchanged over 6.7 million messages with their care teams, with 75% receiving responses in 5 hours or less3. In fact, the majority of customers (73%) preferred their digital health experience with Hims & Hers over other programs or providers4.
  • Care in hours, not months, designed to scale without compromise: The average wait time to see an obesity medicine specialist in the U.S. is approximately 5 months5. In contrast, the average wait time for a Hims & Hers Weight Loss customer to have their online medical intake evaluated by a licensed provider is approximately 3 hours.6

"My two decades as an obesity medicine specialist have shown me that lasting weight loss hinges on treating the individual, not just the condition. The true power of Hims & Hers lies in our ability to deliver access to truly bespoke care: from personalized dosing and tailored nutritional guidance to 24/7 access to reach out to their care team,” said Craig Primack MD, Head of Weight Loss, Hims & Hers. “Medication is a powerful component, but it's just one part of the comprehensive support system people need for this transformative health journey. Today's findings strongly signal that a digital-first, personalized experience is precisely what helps people stick to their treatment plans to drive lasting outcomes."

Download the full white paper here.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

____________________

1

Hims & Hers evaluated de-identified data from 13,458 Weight Loss customers prescribed a compounded injectable GLP-1 medication through our platform who completed a 6-month check. — Hims & Hers, The 1-Year Journey of Hims & Hers Weight Loss Customers, White Paper, 2025.

2

Blue Health Intelligence. (2024). Real-world trends in GLP-1 treatment persistence and prescribing for weight management. https://www.bcbs.com/media/pdf/BHI_Issue_Brief_GLP1_Trends.pdf

3

Hims & Hers Internal Data, as of June 30, 2025

4

Hims & Hers Customer Insights and User Experience Weight Loss Survey, July 2025

5

Rustagi, R. (2023). Regional disparities in access to obesity care: Analysis of wait times in top U.S. hospitals [conference presentation]. World Obesity and Weight Management Congress 2023. Boston, MA. https://obesityworldconference.com/program/scientific-program/2023/regional-disparities-in-access-to-obesity-care-an-analysis-of-wait-times-in-top-u-s-hospitals

6

Hims & Hers Internal Data, as of June 30, 2025

 

Contacts

Press Contact
Susan Cadrecha
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Press Contact
Susan Cadrecha
press@forhims.com
More News From Hims & Hers

Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Dr. Anant Vinjamoori is joining as the Chief Medical Officer of the Hims brand. As the company reimagines how everyone can access proactive, comprehensive care that helps them feel great, Dr. Vinjamoori will provide the clinical guidance that shapes the next phase of the Hims brand across sexual health, hormone health, dermatology, weight loss, and mental health,...

Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligible Canadians. By combining Juniper's proven platform with the technology, data, and clinical infrastructure that has advance...

Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell, Hims & Hers now has a leading presence across the US, UK, Australian, and Canadian markets, with a growing presence in France, Germany, Ireland, Spain, and Japan. Continuing to expand internationally will enable Hims & Hers to lead the next...
Back to Newsroom